Last update 24 Jun 2026

Eli Lilly (Beijing) Medical Technology Innovation Co., Ltd.

Private Company|2024|Beijing Shi, China

Overview

Tags

Endocrinology and Metabolic Disease
Recombinant polypeptide
Small molecule drug

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Nervous System Diseases2
Immune System Diseases2
Endocrinology and Metabolic Disease2
Top 5 Drug TypeCount
Small molecule drug1
Recombinant polypeptide1
Top 5 TargetCount
GLP-1R(Glucagon-like peptide 1 receptor)1
AMYR(Amylin receptor)1

Related

2
Drugs associated with Eli Lilly (Beijing) Medical Technology Innovation Co., Ltd.
Orforglipron
Target
GLP-1R
Mechanism
GLP-1R agonists
Active Org.
Eli Lilly & Co.Eli Lilly & Co. [+3]
Originator Org.
Chugai Pharmaceutical Co., Ltd.Chugai Pharmaceutical Co., Ltd.
Active Indication
Obesity [+14]
Inactive Indication-
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
United States
First Approval Date01 Apr 2026
Eloralintide
Target
AMYR
Mechanism
AMYR agonists
Active Org.
Eli Lilly & Co.Eli Lilly & Co. [+2]
Originator Org.
Eli Lilly & Co.Eli Lilly & Co.
Active Indication
Sleep Apnea, Obstructive [+3]
Inactive Indication-
Drug Highest PhasePhase 3
First Approval Ctry. / Loc.-
First Approval Date-
1
Clinical Trials associated with Eli Lilly (Beijing) Medical Technology Innovation Co., Ltd.
CTR20261932
/ Not yet recruitingPhase 3
一项在肥胖或超重合并膝骨关节炎疼痛的成人参与者中评价Eloralintide每周一次给药的有效性和安全性的随 机、双盲、安慰剂对照、3期研究（ENLIGHTEN-4）
[Translation] A randomized, double-blind, placebo-controlled, phase 3 study (ENLIGHTEN-4) evaluating the efficacy and safety of once-weekly administration of Eloralintide in obese or overweight adult participants with knee osteoarthritis pain.
100 Clinical Results associated with Eli Lilly (Beijing) Medical Technology Innovation Co., Ltd.
Login to view more data
0 Patents (Medical) associated with Eli Lilly (Beijing) Medical Technology Innovation Co., Ltd.
Login to view more data
100 Deals associated with Eli Lilly (Beijing) Medical Technology Innovation Co., Ltd.
Login to view more data
100 Translational Medicine associated with Eli Lilly (Beijing) Medical Technology Innovation Co., Ltd.
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 03 Jul 2026

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Phase 3
1
1
NDA/BLA
Login to view more data

Current Projects

Drug(Targets)IndicationsGlobal Highest Phase
Orforglipron
 ( GLP-1R )		Obesity
More
NDA/BLA
Eloralintide
 ( AMYR )		Obesity
More
Phase 3
Login to view more data

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free